Form 4: Milestone Pharmaceuticals COO Granted Stock Options and Restricted Stock Units
SEC Form 4
Jeffrey Edward Nelson, Chief Operating Officer of Milestone Pharmaceuticals, received stock options and restricted stock units on January 27, 2025.
Summary
- Jeffrey Edward Nelson, the Chief Operating Officer of Milestone Pharmaceuticals Inc., was granted stock options and restricted stock units on January 27, 2025.
- The stock options grant consists of 120,600 shares with an exercise price of $2.02 per share.
- These options vest over time, with one-fourth vesting on January 27, 2026, and the remainder vesting monthly thereafter, contingent upon continued service.
- Nelson also received 80,400 restricted stock units, each representing the right to receive one common share.
- These restricted stock units vest in equal installments on January 27th of 2026, 2027, 2028, and 2029, also contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive indicator.
Positives
- The granting of stock options and restricted stock units aligns the COO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
- The vesting schedules encourage continued service and commitment from the COO.
Industry Context
Equity compensation is a common practice in the pharmaceutical industry to attract and retain key executives and align their interests with those of the shareholders.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation tools for executives in publicly traded pharmaceutical companies.
- Vesting schedules, typically over 3-4 years, are designed to incentivize long-term commitment.
- The specific number of shares and exercise price would need to be compared to similar companies of Milestone's size and stage to determine if they are in line with industry norms.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/27/2025 | Date of the transaction: Grant of stock options and restricted stock units. |
| 01/27/2026 | First vesting date for both stock options and restricted stock units (1/4th of each). |
| 01/27/2027 | Second vesting date for restricted stock units (1/4th). |
| 01/27/2028 | Third vesting date for restricted stock units (1/4th). |
| 01/27/2029 | Final vesting date for restricted stock units (1/4th). |
| 01/27/2035 | Expiration date of the employee stock options. |
| 01/29/2025 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.